arrow
D

Danièle Ouellet

Janssen Research and Development
H指数:35
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results

来自MonumenTAL-1研究的 talquetamab 用于复发/难治性多发性骨髓瘤患者的推荐II期剂量:临床药理学结果

2025-07-240
OAAI
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D x CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
2024-09-160
OAAI
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
2023-09-1521
OAAI
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

在I/II期临床试验中联合使用达拉非尼和曲美替尼治疗的BRAFV600E/K转移性黑色素瘤患者的发热特征

2015-02-0181
OAAI
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
2014-11-131.5K
OAAI